Literature DB >> 28297630

Genomics of Multiple Myeloma.

Sebastien Robiou du Pont1, Alice Cleynen1, Charlotte Fontan1, Michel Attal1, Nikhil Munshi1, Jill Corre1, Hervé Avet-Loiseau1.   

Abstract

Multiple myeloma (MM) is characterized by wide variability in the chromosomal/genetic changes present in tumor plasma cells. Genetically, MM can be divided into two groups according to ploidy and hyperdiploidy versus nonhyperdiploidy. Several studies in gene expression profiling attempted to identify subentities in MM without convincing results. These studies mostly confirmed the cytogenetic data and subclassified patients according to 14q32 translocations and ploidy. More-recent data that are based on whole-exome sequencing have confirmed this heterogeneity and show many gene mutations but without a unifying mutation. These newer studies have shown the frequent alteration of the mitogen-activated protein kinase pathway. The most interesting data have demonstrated subclonality in all patients with MM, including subclonal mutations of supposed driver genes KRAS, NRAS, and BRAF.

Entities:  

Mesh:

Year:  2017        PMID: 28297630     DOI: 10.1200/JCO.2016.70.6705

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  40 in total

1.  Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Authors:  Alice Cleynen; Mehmet Samur; Aurore Perrot; Laure Buisson; Sabrina Maheo; Mariateresa Fulciniti; Michel Attal; Nikhil Munshi; Hervé Avet-Loiseau; Jill Corre
Journal:  Blood       Date:  2018-11-14       Impact factor: 22.113

2.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

Review 3.  Diagnosis and classification of hematologic malignancies on the basis of genetics.

Authors:  Justin Taylor; Wenbin Xiao; Omar Abdel-Wahab
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

4.  Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Authors:  Surbhi Sidana; Dragan Jevremovic; Rhett P Ketterling; Nidhi Tandon; Patricia T Greipp; Linda B Baughn; Angela Dispenzieri; Morie A Gertz; Sundararajan Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2019-02-06       Impact factor: 10.047

Review 5.  BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Authors:  Sarah A Holstein; Hervé Avet-Loiseau; Theresa Hahn; Christine M Ho; Jens G Lohr; Nikhil C Munshi; Bruno Paiva; Marcelo C Pasquini; Joseph D Tario; Saad Z Usmani; Paul K Wallace; Katja Weisel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-11       Impact factor: 5.742

6.  The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Authors:  Sophia Adamia; Ivane Abiatari; Samir B Amin; Mariateresa Fulciniti; Stephane Minvielle; Cheng Li; Philippe Moreau; Herve Avet-Loiseau; Nikhil C Munshi; Kenneth C Anderson
Journal:  Leukemia       Date:  2019-06-10       Impact factor: 11.528

7.  Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma.

Authors:  Arantxa Carrasco-Leon; Teresa Ezponda; Cem Meydan; Luis V Valcárcel; Raquel Ordoñez; Marta Kulis; Leire Garate; Estíbaliz Miranda; Victor Segura; Elisabeth Guruceaga; Amaia Vilas-Zornoza; Diego Alignani; Marién Pascual; Ane Amundarain; Laura Castro-Labrador; Patxi San Martín-Uriz; Halima El-Omri; Ruba Y Taha; Maria J Calasanz; Francisco J Planes; Bruno Paiva; Christopher E Mason; Jesús F San Miguel; José I Martin-Subero; Ari Melnick; Felipe Prosper; Xabier Agirre
Journal:  Leukemia       Date:  2021-02-17       Impact factor: 11.528

Review 8.  Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.

Authors:  Christopher T Su; J Christine Ye
Journal:  J Hematol Oncol       Date:  2021-07-23       Impact factor: 17.388

9.  Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

Authors:  Leo Hansmann; Arnold Han; Livius Penter; Michaela Liedtke; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2017-08-02       Impact factor: 11.151

10.  del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.

Authors:  Jill Corre; Aurore Perrot; Denis Caillot; Karim Belhadj; Cyrille Hulin; Xavier Leleu; Mohamad Mohty; Thierry Facon; Laure Buisson; Laura Do Souto; Romain Lannes; Stephanie Dufrechou; Naïs Prade; Frederique Orsini-Piocelle; Laurent Voillat; Arnaud Jaccard; Lionel Karlin; Margaret Macro; Sabine Brechignac; Mamoun Dib; Laurence Sanhes; Jean Fontan; Lauriane Clement-Filliatre; Jean-Pierre Marolleau; Stephane Minvielle; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.